Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063581) NEW THERAPY FOR OSTEOARTHRITIC PAIN
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. A physiological compound for use in the treatment of osteoarthritic pain in a patient having osteoarthritis wherein the physiological compound is to be administered at least three time per treatment cycle, said administrations being separated by about 1 week.

2. A physiological compound for use for slowing down the structural osteoarthritis progression in a patient having osteoarthritis wherein the physiological compound is to be administered at least three times per treatment cycle, said administrations being separated by about 1 week, preferably by 1 week.

3. The physiological compound for use according to claim 1 or claim 2, wherein said administrations are separated by 1 week.

4. The physiological compound for use according to any of the preceding claims, wherein the physiological compound is to be administered at least 3 times or at least 4 times per treatment cycle.

5. The physiological compound for use according to any of the preceding claims, wherein treatment cycles are repeated after 2, 3, 4, 5 or 6 months.

6. The physiological compound for use according to any of the preceding claims, which comprises 1 , 2, or 3 treatment cycles per year.

7. The physiological compound for use according to any of the preceding claims, wherein the physiological compound is to be administered intra-articularly.

8. The physiological compound for use according to any of the preceding claims, wherein the physiological compound is administered after a step of synovial aspiration.

9. The physiological compound for use according to any one of the preceding claims, wherein the physiological compound is to be administered at a volume of 1-5 ml, or preferably 1 to 3 ml, or more preferably 2 ml per single intra-articular administration.

10. The physiological compound for use according to claim 9, wherein the physiological compound is to be administered at a volume of or of about 1 , 2, 3, 4 or 5 imL per single intra-articular administration of the physiological compound.

1 1. The physiological compound for use according to any one of the preceding claims, wherein the physiological compound is selected from the group of saline, phosphate-buffered saline (PBS), sodium lactate solution or combination of both saline and PBS.

12. The physiological compound for use according to claim 1 1 , wherein saline is at or at about 0.9% w/v.